Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Apogee Therapeutics Inc | APGE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 47.86 | 04:09:34 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 47.86 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 14.19 - 72.29 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 47.86 | USD |
Apogee Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.42B | 50.66M | - | 0 | -83.99M | -1.66 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Apogee Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APGE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 49.29 | 50.21 | 45.6058 | 47.33 | 337,679 | -1.43 | -2.90% |
| 1 Month | 50.42 | 56.10 | 45.6058 | 51.79 | 427,949 | -2.56 | -5.08% |
| 3 Months | 60.23 | 72.29 | 43.605 | 60.28 | 621,989 | -12.37 | -20.54% |
| 6 Months | 17.63 | 72.29 | 17.1685 | 49.86 | 530,419 | 30.23 | 171.47% |
| 1 Year | 21.50 | 72.29 | 14.19 | 40.24 | 441,825 | 26.36 | 122.60% |
| 3 Years | 21.50 | 72.29 | 14.19 | 40.24 | 441,825 | 26.36 | 122.60% |
| 5 Years | 21.50 | 72.29 | 14.19 | 40.24 | 441,825 | 26.36 | 122.60% |
Apogee Therapeutics Description
| Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. |
